Clinical Trials Browser

Phase 3 × patritumab deruxtecan × 90 days × Clear all

NCT07060807 2026-03-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Phase 3 Recruiting

Breast Neoplasms